Prognostic value of high-sensitivity C-reactive protein versus low-density lipoprotein cholesterol for recurrent atherosclerotic cardiovascular disease events using US real-world data
Oct 2026· European Heart Journal· Vol 47· 0 citations
TL;DR
Measuring CV inflammation (hsCRP ≥2 mg/L) could be a potentially valuable means of CV risk prediction in individuals with ASCVD, and hsCRP consistently predicted recurrent CV events and mortality in this US real-world study.
Abstract
Individuals with atherosclerotic cardiovascular disease (ASCVD) are at risk of recurrent cardiovascular (CV) events. High-sensitivity C-reactive protein (hsCRP) is an inflammatory marker that may have predictive value for prevention of recurrent CV events beyond traditional biomarkers, such as low-density lipoprotein cholesterol (LDL-C).
To evaluate the prognostic value of hsCRP relative to LDL-C for recurrent CV events in individuals with established ASCVD, using machine learning (ML)-derived covariates and survival analysis based on US real-world data.
This was a retrospective observational study using the US TriNetX electronic health records and claims data. Included were individuals ≥18 years of age with diagnosis codes for ASCVD between 2010 and 2023 and an eligible hsCRP measurement (index date) at least 30 days after ASCVD diagnosis. hsCRP measurements >10 mg/L or measurements taken in relation to suspected infection or autoimmune disease were excluded. Outcomes of interest were all-cause mortality, ASCVD event recurrence (new ASCVD diagnosis or procedure code in conjunction with a hospitalisation event), the composite of ASCVD event recurrence or all-cause mortality, and 3-point major adverse CV events (non-fatal stroke, non-fatal myocardial infarction or all-cause mortality); outcomes were assessed within a 1-year and a 3-year follow-up period. Cox regression and Fine–Gray competing risk analysis were used to evaluate outcomes in binary (hsCRP ≥2 mg/L vs <2 mg/L; LDL-C ≥55 mg/dL vs <55 mg/dL) and quartile (Q) linear trend (Q1 to Q4 for hsCRP and LDL-C) analyses, using either standard covariates of established CV risk factors or covariates identified through an ML process using SHAP-based feature selection algorithms. In addition, analyses were performed in an internal validation cohort (a subset with available LDL-C measurements within 30 days of index date).
Of 250,591 individuals with ASCVD in the database, 37,639 individuals fulfilled all eligibility criteria. In binary and quartile trend analyses, elevated hsCRP was associated with a significantly increased (p<0.05) risk of all outcomes in year 1 and year 3 (Table 1). No consistent association between elevated LDL-C and risk of outcomes was apparent (Table 2). The results were not affected by covariate selection methods (standard or ML). In the validation cohort (n=22,193), similar trends were observed (Tables 1 and 2).
In this US real-world study of individuals with established ASCVD, hsCRP consistently predicted recurrent CV events and mortality. Measuring CV inflammation (hsCRP ≥2 mg/L) could be a potentially valuable means of CV risk prediction in individuals with ASCVD. A key strength of this study is its use of real-world data, alongside a data-driven ML approach to covariate selection, both of which enhance the clinical relevance and robustness of the findings.For image description, please refer to the figure legend and surrounding text.For image description, please refer to the figure legend and surrounding text.
High-sensitivity C-reactive protein (hsCRP) is a recognized cardiovascular risk-enhancing factor, yet whether its prognostic value varies across the spectrum of baseline cardiovascular risk defined by the American Heart Association (AHA) PREVENT equations remains unknown.
To evaluate the additive prognosti...
V. Jaiswal, A. Bouras, A. Jaiswal et al.· European Heart Journal· 0 citations
Traditional risk factors for atherosclerotic cardiovascular disease (ASCVD) fail to fully reflect the residual risk, driven by chronic low-grade inflammation, observed in many. Generally, high-sensitivity C-reactive protein (hsCRP) concentrations remain stable, but some individuals may experience increases. More...
F. Kahles, M. Reugels, K. Schneider et al.· European Heart Journal· 0 citations
High-sensitivity C-reactive protein (hsCRP) is the guideline-recommended biomarker for assessment of residual inflammatory risk in atherosclerotic cardiovascular disease (ASCVD). Clinical adoption remains limited, especially in individuals without established ASCVD. This study used longitudinal measurements to ev...
B. Kurt, M. Reugels, K. Schneider et al.· European Heart Journal· 0 citations
Systemic inflammation and insulin resistance (IR) are closely linked in cerebrovascular disease. Triglyceride–Glucose (TyG) index and cholesterol–high-density lipoprotein–glucose (CHG) index are proposed markers of IR. Yet no existing biomarker integrates an inflammatory marker with CHG index for stroke risk pred...
Jing-Xian Bai, Guan-Qun Xu, Tai Li et al.· BMC Neurology· 0 citations
Substantial residual cardiovascular risk persists in patients with coronary artery disease (CAD) despite contemporary secondary prevention. While combined assessment of low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) [Lp(a)], and high-sensitivity C-reactive protein (hsCRP) has demonstrated prognostic...
K. Zhang, K. Yan, M. Liu et al.· European Heart Journal· 0 citations
In a large nationwide cohort, recurrent ASCVD events and multi-bed disease were associated with markedly higher mortality compared to patients experiencing single ASCVD events, highlighting the need for earlier, more intensive, and sustained prevention- particularly aggressive LDL-C lowering and comprehensive risk fact...
M. H. Moshe Hoshen, V. B. Vishal Bali, S. Moser et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.